A groundbreaking clinical trial has unveiled a structured, sustainable methodology that significantly reduces maternal infections and deaths, underpinning a new strategy in infection prevention and treatment. This program, known as the Active Prevention and Treatment of Maternal Sepsis (APT-Sepsis), was collaboratively developed by researchers at the University of Liverpool, the World Health Organization (WHO), and the UN’s Special Programme in Human Reproduction (HRP). With findings demonstrating that this program curtails severe maternal infections and death rates by approximately one-third, its importance in global maternal health cannot be overstressed.
As persistent global health issues, maternal infection and sepsis are recognized as leading catalysts for maternal mortality across the world. The scenario grimly displays a death toll involving a mother to sepsis-related causes every half an hour, with the majority of this burden impacting women in low-to-middle income nations. Therefore, the advent of APT-Sepsis intervention provides a beacon of hope by incorporating a comprehensive program targeting three key areas: enhancing hand hygiene, bolstering infection prevention and management, and improving sepsis care with the FAST-M sepsis bundle.
The trial, executed across 59 hospitals in Malawi and Uganda, evaluated the effectiveness of APT-Sepsis by observing over 430,000 women. The study concluded that structured improvements in infection prevention, timely identification, and treatment of maternal sepsis could be a game-changer in maternal healthcare. Even in resource-constrained settings, this innovative program diligently backed healthcare workers in transforming maternal outcomes. The effectiveness of APT-Sepsis, which was found to be consistently beneficial in both Uganda and Malawi, increased gradually across the duration of the trial, culminating in a 47% reduction in the final month.
According to Professor David Lissauer from the University of Liverpool, this significant finding underlines the effectiveness of the APT-Sepsis in curbing preventable maternal deaths due to sepsis. As is echoed by Jeremy Farrar from WHO, the program is an exemplification of the synergy between science, policy, and frontline care, stressing the imperative need for health systems to prioritize infection prevention in maternal care.
The success of the APT-Sepsis program reiterates the fact that structured, system-level approaches that leverage improved practices within existing health systems can eliminate barriers, such as unequal adherence to infection-prevention practices and delays in sepsis treatment. As a low-cost, sustainable program that doesn’t necessitate extensive additional resources, APT-Sepsis positions itself as a scalable model for health programs eager to ameliorate maternal survival on a global scale.
Support for this trailblazing research was provided by a variety of organizations, including the UK Medical Research Council (MRC), the National Institute for Health and Care Research (NIHR), UK AID, the UK Foreign, Commonwealth and Development Office, and MSD for Mothers under the Joint Global Health Trials Scheme.